Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

Pharmacogenomics Journal

Volumn 12, Issue 2, 2012, Pages 119-127

  Kim, H K ^a,b   Choi, I J ^b   Kim, C G ^b   Kim, H S ^b   Oshima, A ^a   Yamada, Y ^c   Arao, T ^d   Nishio, K ^d   Michalowski, A ^a   Green, J E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Cancer Center   (South Korea)

^c NATIONAL CANCER CENTER   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cancer; chemotherapy; expression; gastric; gene

Indexed keywords

AGED; AMPLICON; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FGFR2 GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION RESPONSE; RECEPTOR GENE; STOMACH BIOPSY; STOMACH CANCER;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENES, MYC; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84859000031     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.87     Document Type: Article

References (37)

1. Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastro- intestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; 8: 386.
2. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826-1838. (Pubitemid 46217459)
3. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008; 6: 53-61. (Pubitemid 350309530)
4. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008; 99: 2193-2199.
5. Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res 2008; 14: 6647-6655.
6. Simon R, Radmacher MD, Dobbin K. Design of studies using DNA microarrays. Genet Epidemiol 2002; 23: 21-36. (Pubitemid 34743155)
7. Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al. Randomized phase III trial of capecitabine/cisplatin vs continuous infusion of 5-FU/ cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results. J Clin Oncol 2006; 24 (Suppl): 18s (abstract 4018).
8. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS et al. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 2004; 316: 781-789. (Pubitemid 38372162)
9. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-Array Tools. Cancer Informatics 2007; 2: 11-17. (Pubitemid 47075796)
10. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004; 2: E108.
11. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 2002; 99: 16203-16208. (Pubitemid 35462773)
12. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001; 17: 520-525. (Pubitemid 32600498)
13. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005; 4: 18-25.
14. Chiang YY, Chen SL, Hsiao YT, Huang CH, Lin TY, Chiang IP et al. Nuclear expression of dynamin-related protein 1 in lung adenocarcinomas. Mod Pathol 2009; 22: 1139-1150.
15. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568-574. (Pubitemid 36597103)
16. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000; 60: 5922-5928.
17. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 9: 145-154.
18. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006; 94: 1402-1406. (Pubitemid 43772273)
19. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 2005; 28: 433-438. (Pubitemid 41439735)
20. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 2006; 24: 18s (abstr. 4017).
21. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
22. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs 2008; 13: 135-144. (Pubitemid 351453939)
23. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182. (Pubitemid 26020011)
24. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316. (Pubitemid 28041614)
25. Dobbin KK, Simon RM. Optimally splitting cases for training and testing high dimensional classifiers (submitted for publication) http://linus. nci.nih.gov/Bbrb/reprints.htm.
26. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-1153. (Pubitemid 28440830)
27. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008; 8: 10-15.
28. Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 1993; 4: 33-40.
29. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69-79.
30. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8: 86-94. (Pubitemid 40655517)
31. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-4642. (Pubitemid 23304392)
32. Hiraishi Y, Wada T, Nakatani K, Uchida J, Iwasa T, Yoshida T et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008; 7: 599-606. (Pubitemid 351492458)
33. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T et al. Synergistic anti-tumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010; 126: 1004-1016.
34. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999; 5: 2588-2595. (Pubitemid 29437346)
35. Xie XK, Yang DS, Ye ZM, Tao HM. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest 2006; 24: 1-8.
36. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 2003; 14: 39-47. (Pubitemid 36177353)
37. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004; 6: 195-206. (Pubitemid 38657075)